Gail Lewis Philips
Job title: Senior Scientist
My laboratory studies receptor tyrosine kinases as targets for development of anti-cancer therapeutics, with emphasis on the HER2/erbB2 pathway. Our early research efforts focused on the role of HER2 in HER2-amplified breast cancer, and the biological effects of antibodies directed against HER2. This work led to the development and approval of both Trastuzumab and Pertuzumab. More recently, we developed antibody-drug conjugates (ADCs) designed to selectively deliver potent cytotoxic agents to HER2-positive tumor cells. One of these ADCs, trastuzumab emtansine (T-DM1) was FDA-approved in February 2013. We are currently exploring use of T-DM1 in other cancers that overexpress HER2 as well as investigating new HER2-directed ADCs utilizing cytotoxic agents with different mechanisms than DM1. My lab also performs studies to evaluate activity of novel anti-cancer agents, as free drugs and ADCs, as well as novel antibody formats, for other Oncology indications.